Dementia could affect 778 000 Canadians by the year 2031. While curren
t treatment is mainly supportive, a race to find new treatments for th
is dreaded disease takes varied approaches and currently accounts for
10% of drug company resources. Tacrine is the first drug licensed by t
he US Food and Drug Administration for use in Alzheimer's disease. New
treatments raise several ethical issues and involve society's attitud
e toward death and dying.